NCT06669169尚未招募2 期
A Randomized, Placebo-Controlled, Double-Blind and Multi-Centre Phase II Clinical Trial：Efficacy and Safety of Jia Shen Tablets in the Treatment of Coronary Heart Disease Complicating Chronic Heart Failure (Syndrome of Yang Qi Deficiency With Blood Stasis)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 288
- 试验地点
- 1
- 主要终点
- 6-Minutes-Walking-Distance (6MWD): the change from baseline to Week 12.
研究概览
简要总结
Evaluate the efficacy and safety of Jia Shen Tablets in patients with Chronic Heart Failure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 40-79 years, either sex;
- •Meet the diagnostic criteria for CHD and CHF;
- •Meet the TCM differentiation criteria of yang qi deficiency and blood stasis in CHF;
- •Class Ⅱ to Ⅲ for NYHA functional classification;
- •Willing to provide written informed consent.
排除标准
- •CHF with acute exacerbation or intravenous drug therapy;
- •Received cardiac resynchronization therapy (CRT) or other heart failure devices;
- •Within 3 months before randomization, acute coronary syndrome（ACS）, stroke or transient ischemic attack（TIA） occurred or received cardiac revascularization (PCI, CABG);
- •Plan to undergo cardiac revascularization (PCI, CABG) or cardiac resynchronization therapy (CRT) during the trial period;
- •Severe arrhythmias [such as persistent atrial fibrillation, permanent atrial fibrillation, ventricular tachycardia, second-degree type II or higher sinus or atrioventricular block without pacemaker placement, QT interval (QTc) exceeding 480 ms after heart rate adjustment according to Fridericia's formula, or known history or symptoms of long QT syndrome];
- •Severe hypertension (systolic blood pressure ≥180mm Hg or diastolic blood pressure ≥110mm Hg) or hypotension (systolic blood pressure < 90 mmHg);
- •Heart failure caused by other cardiovascular diseases such as congenital heart disease, severe stenosis or insufficiency of heart valves, cardiomyopathy (e.g. hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, dilated cardiomyopathy, alcoholic cardiomyopathy), moderate pericardial effusion, constrictive pericarditis, and infective endocarditis;
- •Combined with liver, kidney, hematopoietic system and other serious primary diseases, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 3 times the upper limit of local laboratory normal value, the estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2, Blood potassium > 5.5 mmol/L or hemoglobin (Hb) < 90 g/L; Malignant tumors, severe neuroendocrine system diseases and mental diseases;
- •Pregnant or lactating;
- •Participating in other interventional clinical studies within 1 month before screening;
- •Allergic constitution, or allergic to Chinese medicines of Jia Shen Tablets (such as Periploca sepium, salvia miltiorrhiza, etc.);
- •The investigator determines that the patient is unable to complete the study or comply with the requirements of the study.
研究组 & 干预措施
Placebo group
Placebo Comparator
干预措施: Jia Shen Tablet Placebo (Drug)
Low dose group
Experimental
干预措施: Low dose Jia Shen Tablet (Drug)
High dose group
Experimental
干预措施: High dose Jia Shen Tablet (Drug)
结局指标
主要结局
6-Minutes-Walking-Distance (6MWD): the change from baseline to Week 12.
时间窗: Baseline and Week 12.
次要结局
- 6-Minutes-Walking-Distance (6MWD): the change from baseline to Week 6.(Baseline and Week 6.)
- NT-proBNP: the change from baseline to Week 6 and 12.(Baseline, Week 6 and 12.)
- NT-proBNP: the proportion of patients demonstrating a decrease in NT-proBNP level of at least 30%.(Baseline, Week 6 and 12.)
- Echocardiogram: Measurements will be made of the left ventricle's end diastolic diameter (LVEDD), end diastolic volume (LVEDV), end systolic volume (LVESV), left ventricular ejection fraction（LVEF）, stroke volume (SV), and cardiac output (CO).(Baseline and Week 12.)
- NYHA functional classification: Measure the percentage of participants whose NYHA functional classification is improved/worsened/unchanged from baseline to Week 6 and 12.(Baseline, Week 6 and 12.)
- MLHFQ Score: the change from baseline to Week 6 and 12.(Baseline, Week 6 and 12.)
- Traditional Chinese Medicine（TCM） Syndrome Score: change from baseline to Week 6 and 12.(Baseline, Week 6 and 12.)
- Dyspnea, weakness and edema: the rate of disappearance of the symptoms (dyspnea, weakness, and edema) from baseline to Week 6 and 12.(Baseline, Week 6 and 12.)
- Cardiovascular Adverse Events: Incidence of Cardiovascular AEs（cardiovascular death, hospitalization for worsening heart failure, hospitalization for nonfatal myocardial infarction, hospitalization for nonfatal stroke）.(Week 12.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
DANHEART (H-HeFT and Met-HeFT)Heart FailureDiabetesNCT03514108Henrik Wiggers1,100
尚未招募
4 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan CapsulesMajor Depressive Disorder (MDD)NCT06749470480
招募中
1 期
Efficacy Assessment of Chinese Herbal Medicine Jiangtang Tiaozhi Recipe Treating Participants With Glucose and Lipid Metabolism DisturbancesDyslipidemiasType2 DiabetesNCT04623567Guang'anmen Hospital of China Academy of Chinese Medical Sciences96
已完成
1 期
A Study to Evaluate the Tolerability and Pharmacokinetics of Jiashen Tablets in Healthy SubjectsHealthyNCT04164290Tasly Pharmaceutical Group Co., Ltd70
已完成
2 期
Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic GastritisGastritisNCT04672018University of Karachi240